Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, ...

A new study highlights the risks of atopic dermatitis flare-ups after discontinuing dupilumab and the likelihood of ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun ...

Jaina Patel was in her early 30s when a bout of bronchitis led to her losing weight, her job, and eventually her sense of ...

Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children ...